INTRODUCTION {#s1}
============

Leber congenital amaurosis (LCA; OMIM\#204000) is one of the most common causes of childhood blindness, accounting for 5% of all inherited retinal dystrophies and occurring in 2--3 out of 100,000 newborns ([@MCS004481RAGC3]). It is characterized by the onset of severe visual impairment at birth or during infancy and is often accompanied by nystagmus, sluggish pupils, and severely abnormal or nondetectable electroretinogram (ERG) ([@MCS004481RAGC3]; [@MCS004481RAGC12]). LCA is phenotypically and genetically heterogeneous, with as many as 24 known genes involved in its pathogenesis ([@MCS004481RAGC12]). Understanding the underlying genetic basis of LCA is therefore crucial to determining an appropriate and effective treatment course, including potential gene-specific, pharmacological, or pharmacogenetic therapies and interventions ([@MCS004481RAGC4]).

Mutations in *PROM1* (NM_006017.2; OMIM\#604365) have been documented in the literature as manifesting in myriad complications involving the visual system and specifically result in inherited retinal dystrophies such as autosomal dominant and autosomal recessive retinitis pigmentosa (RP) and cone-rod dystrophy ([@MCS004481RAGC8]). In this study, we identify two novel frameshift variants in *PROM1* and expand the phenotypes of *PROM1*-associated disease to include the clinical manifestation of LCA.

RESULTS {#s2}
=======

A 12-yr-old male of Asian descent was referred to the Edward S. Harkness Eye Institute at Columbia University Irving Medical Center because of suspected presence of rod-cone dystrophy. The patient presented with slight photodysphoria and nystagmus beginning at the age of 2 yr and also experienced poor vision at the age of 3 yr and began wearing glasses at this time. He demonstrated a history of continually decreased visual acuity. His medical history was unremarkable with the exception of visual abnormalities. There was no known family history of rod-cone dystrophy or other eye diseases. The patient had not been taking any ocular or systemic medications. Upon examination, the patient\'s best-corrected visual acuity was 20/80 in the right eye (OD) and 20/70 in the left eye (OS). Pendular horizontal nystagmus was observed. When examined, anterior segments appeared to be quiet, and the lenses appeared clear. Intraocular tension was 15 mmHg (OD) and 14 mmHg (OS). The patient\'s dilated fundus examination demonstrated that the optic nerves had good rims. An extensive mottled appearance outside the maculae and a bull\'s eye pattern of continuous atrophy in the maculae were observed ([Fig. 1](#MCS004481RAGF1){ref-type="fig"}).

![Retinal phenotype of a patient with Leber congenital amaurosis (LCA) due to compound heterozygous mutations in the *PROM1* gene. (*A*) Wide-angle fundus photograph of the right and left eyes showing thinning of the vessels. No pigmentary clumps were seen. (*B*) Short-wavelength autofluorescence images showing absent signal on the periphery and a bull\'s eye appearance at the fovea. (*C*) SD-OCT unveils a blurred ellipsoid zone line at the fovea that is absent on the periphery in both eyes. The internal layers are well delineated.](MCS004481Rag_F1){#MCS004481RAGF1}

Full-field electroretinography (ffERG) demonstrated that scotopic rod-specific responses, maximum ERG, photopic 30-Hz flicker ERG, and transient photopic ERG were extinguished ([Fig. 2](#MCS004481RAGF2){ref-type="fig"}).

![Electroretinogram testing. Scotopic and photopic responses were extinguished in both eyes.](MCS004481Rag_F2){#MCS004481RAGF2}

The patient\'s presentation of early-onset nystagmus, poor vision, and extinguished ERG were consistent with a form of LCA. The patient was diagnosed with LCA at the age of 12 yr old with ERG, imaging, genetic testing, and ophthalmic examination conducted at this same time. Whole-exome sequencing results from the patient and his parents revealed that the patient was compound heterozygous for two deleterious variants, c.139del:p.His47Ilefs\*12 and c.1877_1878del:p.Ile626Argfs\*6, in the *PROM1* gene. The c.139del variant was inherited maternally, and the c.1877_1878del variant was inherited paternally ([Table 1](#MCS004481RAGTB1){ref-type="table"}; [Fig. 3](#MCS004481RAGF3){ref-type="fig"}).

![The affected patient\'s inheritance of two heterozygous frameshift variants in the *PROM1* gene. Family pedigree with *arrow* indicating the proband. Black symbol represents clinically affected subject. Black dot in center of symbols represents carriers. An asterisk indicates that this subject was not genetically tested.](MCS004481Rag_F3){#MCS004481RAGF3}

###### 

Summary of the variants reported in this study

  Gene      Chromosome                           HGVS DNA reference   HGVS protein reference   Variant type   Predicted effect (substitution, deletion, etc.)   dbSNP/dbVar ID   Genotype (heterozygous/homozygous)   Sample    Percentage of reads aligned   Average read coverage   Percentage of *SLC52A* **2** sites (1354 bases) with ≥10-fold coverage
  --------- ------------------------------------ -------------------- ------------------------ -------------- ------------------------------------------------- ---------------- ------------------------------------ --------- ----------------------------- ----------------------- ------------------------------------------------------------------------
  *PROM1*   Chr 4: 16077391delG (GRCh37/hg19)    c.139del             p.His47Ilefs\*l2         Frameshift     Frameshift deletion                               rs747512450      Heterozygous                         Proband   99.003                        181.53                  98.936
  *PROM1*   Chr 4: 15993904delTA (GRCh37/hg19)   c.1877_1878del       p.Ile626Argfs\*6         Frameshift     Frameshift deletion                               rs1300041533     Heterozygous                                                                                         

DISCUSSION {#s3}
==========

In this report, we present a unique case of an individual with two not previously described deleterious variants in the *PROM1* gene that cause LCA. The patient\'s early childhood onset of severe visual impairment, along with his clinical presentation of nystagmus and extinguished ffERG, were consistent with the symptoms of LCA. Differential diagnoses of severe early childhood--onset retinal dystrophy (SECORD) and early-onset RP were eliminated based on the patient\'s extinguished ffERG results, as ffERG is typically detectable (although diminished) in patients with SECORD or early-onset RP ([@MCS004481RAGC4]).

Whole-exome sequencing analysis of the affected individual identified two compound heterozygous frameshift variants, c.139del:p.His47Ilefs\*12 in exon 1 and c.1877_1878del:p.Ile626Argfs\*6 in exon 16, in *PROM1* (NM_006017.2; OMIM\#604365). Among the 27 total exons in *PROM1*, the c.139del variant was found to replace the His47 residue with Ile in the extracellular amino-terminal E1 domain in exon 1, whereas the c.1877_1878del variant replaced the Ile626 residue with Arg in the extracellular large glycosylated E2 domain in exon 16 ([Fig. 4](#MCS004481RAGF4){ref-type="fig"}). Both changes result in the premature termination of translation and are predicted to undergo nonsense-mediated decay, leading to the loss of PROM1 protein.

![Deleterious frameshift variants in the PROM1 protein. Structural representation of the extracellular amino-terminal E1 domain in exon 1 and the Ile626 residue with Arg in the extracellular large glycosylated E2 domain with two residues affected by frameshift variants in our patient in red.](MCS004481Rag_F4){#MCS004481RAGF4}

Previous studies have demonstrated that PROM1 may play an important role in photoreceptor morphology and autophagy in retinal pigment epithelium (RPE) cells. For example, *PROM1* mutations in CHO cells have been suggested to impair synthesis of evaginations at the outer segments of rod photoreceptors or impair conversion of these evaginations to disks ([@MCS004481RAGC6]). In the RPE, PROM1 may be involved in mediating autophagy by impeding mTOR signaling and acting with p62 and HDAC6 in a macromolecular scaffold implicated in autophagosome maturation and trafficking ([@MCS004481RAGC1]). Thus, loss or absence of PROM1 caused by truncating mutations may disrupt these processes and lead to aberrant signaling that results in retinal disease. However, the mechanism by which *PROM1* causes LCA specifically, rather than RP or other retinal dystrophies, has not yet been investigated and is currently unknown.

To our knowledge, this is the first report to associate mutations in the *PROM1* gene with the LCA phenotype. Autosomal recessive inheritance of *PROM1* variants is associated with RP, cone-rod dystrophy and RP with macular degeneration and autosomal dominant inheritance of *PROM1* variants is associated with cone-rod dystrophy, Stargardt-like macular dystrophy, and bull\'s eye macular dystrophy ([@MCS004481RAGC16]; [@MCS004481RAGC14]; [@MCS004481RAGC2]; [@MCS004481RAGC13]; [@MCS004481RAGC5]). For example, [@MCS004481RAGC10] reports two patients with biallelic truncating mutations in *PROM1* that manifest in severe RP. These patients differ from our patient because of the absence of nystagmus in one patient, and both cases report RP symptoms beginning in adulthood, whereas our patient presented with pendular horizontal nystagmus and vision loss starting at the age of 2--3 yr, as is consistent with the diagnosis of LCA ([@MCS004481RAGC10]). Other reports have also found that missense *PROM1* mutations are linked to autosomal dominant Stargardt-like or bull\'s eye macular dystrophy, whereas nonsense and frameshift mutations result in RP, severe cone-rod dystrophy with macular degeneration, and night blindness ([@MCS004481RAGC10]). Our study highlights two novel *PROM1* variants that expand the genetic basis of LCA and the possible clinical presentations that can be caused by *PROM1* mutations. These findings may influence future gene-based therapies for LCA as well as pave the way for mechanistic studies that elucidate the pathogenesis of *PROM1*-mediated LCA.

METHODS {#s4}
=======

Genetic Analyses {#s4b}
----------------

Whole-exome sequencing was performed on peripheral blood obtained from the affected individual. Agilent SureSelectXT Human All Exon V5 + UTRs capture and Illumina HiSeq2500 sequencing technology were used for the detection of pathogenic mutations, which were analyzed with the NextGENe software from SoftGenetics and the proprietary analytical pipeline of the Laboratory of Personalized Genomic Medicine (PGM), Department of Pathology and Cell Biology, Columbia University.

This test was developed and its performance characteristics determined by the Molecular Pathology Laboratory of Columbia University. The test methodology has been validated in-house, and the methodology and validation data have been reviewed by the Clinical Laboratory Evaluation Program of the New York State Department of Health. The laboratory also participates in interlaboratory testing under the auspices of the College of American Pathologists, in keeping with the Clinical Laboratory Improvement Amendments of 1988 (CLIA 88). Therefore, this test is used for clinical purposes. It should not be regarded as investigational or for research on this basis alone.

Electroretinography {#s4c}
-------------------

ffERG (Diagnosys, LLC) was performed with Dawson, Trick, and Litzkow (DTL) fiber electrodes and Ganzfield stimulation according to international standards. Additionally, recordings were obtained for our patient for both eyes in accordance with the International Society for Clinical Electrophysiology of Vision (ISCEV) guidelines in both the scotopic and photopic states ([@MCS004481RAGC7]). The amplitudes and implicit times recorded for each eye of the patient were compared to age-matched control patients with normal values.

Imaging {#s4d}
-------

All imaging procedures were performed according to the methodology described by [@MCS004481RAGC11]. The patient\'s eyes were dilated and then ophthalmic assessment including funduscopic examination, digital fundus photography, and both fundus short-wavelength autofluorescence (SW-AF) and spectral domain optical coherence tomography (SD-OCT) imaging were performed. SW-AF (488-nm wavelength stimulus, barrier filtered transmitted light from 500 to 680 nm, 55° × 55° field) and SD-OCT images were acquired, utilizing a confocal scanning laser ophthalmoscope (cSLO; Spectralis HRA + OCT, Heidelberg Engineering). The patient\'s eyes were dilated by administering 1% tropicamide and 2.5% phenylephrine. SD-OCT images were obtained as horizontal 9 × 9-mm scans (870-nm light source and 7-µM axial resolution) positioned through the macula and obtained in high-resolution mode. The scans were recorded automatically by the use of recorded IR-R (820-nm light source) fundus images.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The association between these two variants and LCA described in this study has been submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>). The NM_006017.2: p.(His47Ilefs\*12) frameshift variant can be accessed through dbSNP rs148234606 and ClinVar SCV000996524. The NM\_:p.(p.Ile626Argfs\*6) frameshift variant can be accessed through dbSNP rs375088539 and ClinVar SCV000996523.

Ethics Statement {#s5b}
----------------

The family consented to this genetic study and gave permission for the publication of genetic and clinical results. A retrospective analysis of one patient diagnosed with LCA who presented to the Department of Ophthalmology at Edward S. Harkness Eye Institute, Columbia University was performed. The study followed the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board at Columbia University Medical Center (protocol \#AAAR0284). As per a retrospective study with no more than a minimal risk for the subject, this study did not require written consent by IRB policies.
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